Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis

[1]  H. Prüss,et al.  Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics , 2018, Journal of Neurology.

[2]  Anne-Kathrin Kienzler,et al.  The clinical features, underlying immunology, and treatment of autoantibody‐mediated movement disorders , 2018, Movement disorders : official journal of the Movement Disorder Society.

[3]  K. Chu,et al.  Bortezomib treatment for severe refractory anti‐NMDA receptor encephalitis , 2018, Annals of clinical and translational neurology.

[4]  M. Farrell,et al.  Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab , 2018, Clinical case reports.

[5]  F. Shi,et al.  Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder , 2017, JAMA neurology.

[6]  F. Hiepe,et al.  Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis , 2017, Neurology.

[7]  A. Palumbo,et al.  Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2016, Blood.

[8]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[9]  J. Dalmau,et al.  The clinical spectrum of Caspr2 antibody–associated disease , 2016, Neurology.

[10]  Bie M. P. Verbist,et al.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.

[11]  Andreas Radbruch,et al.  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.

[12]  Andreas Radbruch,et al.  Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus , 2012, Annals of the rheumatic diseases.